BIOD 102 Portage Learning - Lab 2 Exam
(Hyperinsulinemia) (2026/2027)
Section 1: Hyperinsulinemia – Definition, Causes, Mechanisms
Section 2: Insulin Resistance & Compensatory Hyperinsulinemia
Section 3: Clinical Consequences & Diagnostic Methods
Section 4: Laboratory Assessment & Data Interpretation
Q1: According to the 2026/2027 metabolic physiology guidelines used in the BIOD 102 Portage
Learning lab, which of the following correctly defines fasting hyperinsulinemia?
A. Fasting insulin >15 μIU/mL with elevated fasting glucose
B. Fasting insulin >25 μIU/mL with normal or elevated fasting glucose [CORRECT]
C. Fasting insulin >25 μIU/mL with documented fasting hypoglycemia
D. Fasting insulin >10 μIU/mL with low fasting glucose
Correct Answer: B
Rationale: Fasting hyperinsulinemia in the context of insulin resistance is defined as a fasting
insulin level greater than 25 μIU/mL, typically accompanying normal or elevated blood glucose.
Hypoglycemia with high insulin defines hyperinsulinemic hypoglycemia, not standard metabolic
hyperinsulinemia.
Q2: A virtual patient presents with a fasting glucose of 88 mg/dL and a fasting insulin level of 32
μIU/mL, but reports episodic palpitations and confusion that resolve only with eating. Which of
the following is the most likely cause of this patient's lab profile?
A. Metabolic syndrome
B. Polycystic ovary syndrome (PCOS)
C. Insulinoma [CORRECT]
D. Exogenous corticosteroid use
.
,Correct Answer: C
Rationale: While metabolic syndrome and PCOS cause hyperinsulinemia with normoglycemia
due to resistance, the presence of symptomatic hypoglycemia (palpitations, confusion relieved by
eating) strongly suggests an insulinoma, an insulin-secreting tumor that causes inappropriate,
autonomous insulin release.
Q3: In a Portage Learning virtual lab experiment, hepatic cells are exposed to high chronic
insulin levels but fail to suppress hepatic glucose output. Which mechanism best explains this
finding?
A. Upregulation of GLUT2 transporters causing excessive glucose uptake
B. Enhanced glucagon secretion overriding insulin's effect
C. Downregulation of insulin receptors and post-receptor signaling defects [CORRECT]
D. Increased beta-cell apoptosis reducing circulating insulin levels
Correct Answer: C
Rationale: Hepatic insulin resistance is primarily driven by the downregulation of insulin
receptors and defects in intracellular post-receptor signaling pathways (e.g., impaired IRS-1
phosphorylation), which prevent insulin from adequately suppressing gluconeogenesis and
glycogenolysis.
Q4: A 45-year-old patient is prescribed high-dose glucocorticoids for an autoimmune condition.
Over three months, their fasting insulin increases from 12 μIU/mL to 28 μIU/mL, while glucose
remains at 95 mg/dL. What is the primary mechanism driving this secondary hyperinsulinemia?
A. Glucocorticoids directly stimulate pancreatic beta-cell hypertrophy
B. Glucocorticoids increase peripheral insulin resistance, requiring compensatory
hyperinsulinemia [CORRECT]
C. Glucocorticoids inhibit renal insulin clearance mechanisms
D. Glucocorticoids increase GLUT4 transporter expression in skeletal muscle
Correct Answer: B
Rationale: Glucocorticoids induce peripheral insulin resistance by altering post-receptor
signaling and promoting muscle catabolism. The pancreas compensates by secreting more insulin
(hyperinsulinemia) to maintain euglycemia, which explains the elevated insulin with normal
glucose.
.
, Q5: In the Portage Learning virtual lab, you analyze adipose tissue samples from an obese mouse
model and note elevated free fatty acids (FFAs) alongside high local insulin levels. What is the
primary metabolic consequence of these elevated FFAs?
A. FFAs bind to insulin receptors, increasing glucose uptake
B. FFAs promote ectopic lipid deposition in liver and muscle, exacerbating insulin
resistance [CORRECT]
C. FFAs inhibit lipolysis, thereby reducing ectopic fat deposition
D. FFAs are rapidly converted to ketones, which lower blood glucose
Correct Answer: B
Rationale: Insulin-resistant adipose tissue fails to adequately suppress lipolysis, releasing excess
FFAs into the circulation. These FFAs are deposited ectopically in the liver and skeletal muscle,
activating inflammatory pathways that further impair insulin signaling.
Q6: During the early stages of insulin resistance, pancreatic beta cells increase their secretory
capacity to maintain normal blood glucose. Which structural and functional changes occur in the
beta cells during this compensatory phase?
A. Beta-cell apoptosis and reduced islet mass
B. Beta-cell dedifferentiation into alpha cells
C. Beta-cell hypertrophy, hyperplasia, and increased insulin secretion [CORRECT]
D. Decreased proinsulin synthesis due to endoplasmic reticulum stress
Correct Answer: C
Rationale: To overcome peripheral insulin resistance and maintain normoglycemia, pancreatic
beta cells undergo compensatory hypertrophy (increase in cell size) and hyperplasia (increase in
cell number), resulting in an increased basal and stimulated secretion of insulin.
Q7: In a Portage Learning experimental design module, researchers isolate pancreatic islets from
two groups of mice: Group A (lean) and Group B (obese). When exposed to a high glucose
concentration, Group B islets secrete twice as much insulin as Group A. What does this data
indicate about Group B?
A. Group B has severe beta-cell failure
.
(Hyperinsulinemia) (2026/2027)
Section 1: Hyperinsulinemia – Definition, Causes, Mechanisms
Section 2: Insulin Resistance & Compensatory Hyperinsulinemia
Section 3: Clinical Consequences & Diagnostic Methods
Section 4: Laboratory Assessment & Data Interpretation
Q1: According to the 2026/2027 metabolic physiology guidelines used in the BIOD 102 Portage
Learning lab, which of the following correctly defines fasting hyperinsulinemia?
A. Fasting insulin >15 μIU/mL with elevated fasting glucose
B. Fasting insulin >25 μIU/mL with normal or elevated fasting glucose [CORRECT]
C. Fasting insulin >25 μIU/mL with documented fasting hypoglycemia
D. Fasting insulin >10 μIU/mL with low fasting glucose
Correct Answer: B
Rationale: Fasting hyperinsulinemia in the context of insulin resistance is defined as a fasting
insulin level greater than 25 μIU/mL, typically accompanying normal or elevated blood glucose.
Hypoglycemia with high insulin defines hyperinsulinemic hypoglycemia, not standard metabolic
hyperinsulinemia.
Q2: A virtual patient presents with a fasting glucose of 88 mg/dL and a fasting insulin level of 32
μIU/mL, but reports episodic palpitations and confusion that resolve only with eating. Which of
the following is the most likely cause of this patient's lab profile?
A. Metabolic syndrome
B. Polycystic ovary syndrome (PCOS)
C. Insulinoma [CORRECT]
D. Exogenous corticosteroid use
.
,Correct Answer: C
Rationale: While metabolic syndrome and PCOS cause hyperinsulinemia with normoglycemia
due to resistance, the presence of symptomatic hypoglycemia (palpitations, confusion relieved by
eating) strongly suggests an insulinoma, an insulin-secreting tumor that causes inappropriate,
autonomous insulin release.
Q3: In a Portage Learning virtual lab experiment, hepatic cells are exposed to high chronic
insulin levels but fail to suppress hepatic glucose output. Which mechanism best explains this
finding?
A. Upregulation of GLUT2 transporters causing excessive glucose uptake
B. Enhanced glucagon secretion overriding insulin's effect
C. Downregulation of insulin receptors and post-receptor signaling defects [CORRECT]
D. Increased beta-cell apoptosis reducing circulating insulin levels
Correct Answer: C
Rationale: Hepatic insulin resistance is primarily driven by the downregulation of insulin
receptors and defects in intracellular post-receptor signaling pathways (e.g., impaired IRS-1
phosphorylation), which prevent insulin from adequately suppressing gluconeogenesis and
glycogenolysis.
Q4: A 45-year-old patient is prescribed high-dose glucocorticoids for an autoimmune condition.
Over three months, their fasting insulin increases from 12 μIU/mL to 28 μIU/mL, while glucose
remains at 95 mg/dL. What is the primary mechanism driving this secondary hyperinsulinemia?
A. Glucocorticoids directly stimulate pancreatic beta-cell hypertrophy
B. Glucocorticoids increase peripheral insulin resistance, requiring compensatory
hyperinsulinemia [CORRECT]
C. Glucocorticoids inhibit renal insulin clearance mechanisms
D. Glucocorticoids increase GLUT4 transporter expression in skeletal muscle
Correct Answer: B
Rationale: Glucocorticoids induce peripheral insulin resistance by altering post-receptor
signaling and promoting muscle catabolism. The pancreas compensates by secreting more insulin
(hyperinsulinemia) to maintain euglycemia, which explains the elevated insulin with normal
glucose.
.
, Q5: In the Portage Learning virtual lab, you analyze adipose tissue samples from an obese mouse
model and note elevated free fatty acids (FFAs) alongside high local insulin levels. What is the
primary metabolic consequence of these elevated FFAs?
A. FFAs bind to insulin receptors, increasing glucose uptake
B. FFAs promote ectopic lipid deposition in liver and muscle, exacerbating insulin
resistance [CORRECT]
C. FFAs inhibit lipolysis, thereby reducing ectopic fat deposition
D. FFAs are rapidly converted to ketones, which lower blood glucose
Correct Answer: B
Rationale: Insulin-resistant adipose tissue fails to adequately suppress lipolysis, releasing excess
FFAs into the circulation. These FFAs are deposited ectopically in the liver and skeletal muscle,
activating inflammatory pathways that further impair insulin signaling.
Q6: During the early stages of insulin resistance, pancreatic beta cells increase their secretory
capacity to maintain normal blood glucose. Which structural and functional changes occur in the
beta cells during this compensatory phase?
A. Beta-cell apoptosis and reduced islet mass
B. Beta-cell dedifferentiation into alpha cells
C. Beta-cell hypertrophy, hyperplasia, and increased insulin secretion [CORRECT]
D. Decreased proinsulin synthesis due to endoplasmic reticulum stress
Correct Answer: C
Rationale: To overcome peripheral insulin resistance and maintain normoglycemia, pancreatic
beta cells undergo compensatory hypertrophy (increase in cell size) and hyperplasia (increase in
cell number), resulting in an increased basal and stimulated secretion of insulin.
Q7: In a Portage Learning experimental design module, researchers isolate pancreatic islets from
two groups of mice: Group A (lean) and Group B (obese). When exposed to a high glucose
concentration, Group B islets secrete twice as much insulin as Group A. What does this data
indicate about Group B?
A. Group B has severe beta-cell failure
.
